基本信息:
- 专利标题: 약독화 페스티바이러스를 포함하는 백신
- 专利标题(英):Vaccine comprising a live attenuated pestivirus
- 专利标题(中):약독화페스티바이러스를포함하는백신
- 申请号:KR1020067026800 申请日:2005-05-18
- 公开(公告)号:KR100908798B1 公开(公告)日:2009-07-22
- 发明人: 메이어스그레고르 , 에게안드레아스 , 페처크리스티안 , 폰프레이부르크마르티나
- 申请人: 베링거잉겔하임베트메디카게엠베하
- 申请人地址: ***** Ingelheim, Germany
- 专利权人: 베링거잉겔하임베트메디카게엠베하
- 当前专利权人: 베링거잉겔하임베트메디카게엠베하
- 当前专利权人地址: ***** Ingelheim, Germany
- 代理人: 장훈; 이범래
- 优先权: DE10 2004 025 4524 2004-05-19
- 国际申请: PCT/EP2005/005377 2005-05-18
- 国际公布: WO2005111201 2005-11-24
- 主分类号: A61K39/15
- IPC分类号: A61K39/15
摘要:
The present invention relates to attenuated pestivurses, in particular to attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Erns and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Erns in addition to the inactivation of the (hypothesized) immunemodulating activity residing in Npro.The invention also relates to methods for attenuating pestiviruses such as BVDV, nucleic acids encoding said pestiviruses, in particular BVDV, compositions and vaccines comprising the attenuated pestiviruses, in particular BVDV of the invention.
摘要(中):
本发明涉及减毒腮腺炎,尤其是减毒BVDV,其中至少一个突变位于糖蛋白Erns的编码序列中,并且Npro的编码序列中至少有另一个突变,其优选导致存在于组织中的RNase活性的联合失活 (假设的)免疫调节活性的失活以及Npro中的(假设的)免疫调节活性的灭活。本发明还涉及用于减毒瘟病毒例如BVDV,编码所述瘟病毒的核酸,特别是BVDV,包含减毒瘟病毒的组合物和疫苗 本发明的特定BVDV。
公开/授权文献:
- KR1020070012862A 약독화 페스티바이러스를 포함하는 백신 公开/授权日:2007-01-29
信息查询:
EspacenetIPC结构图谱:
A | 人类生活必需 |
--A61 | 医学或兽医学;卫生学 |
----A61K | 医用、牙科用或梳妆用的配制品 |
------A61K39/00 | 含有抗原或抗体的医药配制品 |
--------A61K39/12 | .病毒性抗原 |
----------A61K39/15 | ..呼肠病毒科,如小牛腹泻病毒 |